Investor Presentaiton

Made public by

sourced by PitchSend

5 of 34

Creator

PitchSend logo
PitchSend

Category

Pending

Published

Unknown

Slides

Transcriptions

#1Brain ResourceⓇ Investor Presentation October 2018 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#2DISCLAIMER: Brain ResourceⓇ This presentation is issued by Brain Resource Limited (ASX: BRC) ("Brain Resource", "Total Brain", "MBS", "the Company" or "we") to you, is to be held confidentially by you and may not be shared by you with third parties. This presentation is general background information about the Company's activities current as at the date of this presentation. The information is given in summary form and does not purport to be complete. This presentation is not an offer to sell, or any sale, of securities. Any offer and sale of securities would be done only pursuant to a written agreement between Brain Resource and its investors. Brain Resource has made every effort to ensure that the information in this presentation is accurate. However, its accuracy, reliability or completeness cannot be assured. To the maximum extent permitted by law, we and our associates, respective officers, employees and agents, disclaim any liability for any error or omission or for any loss suffered as a result of others acting on the basis of the information contained in this document. In particular this presentation includes forward looking statements (e.g. phrases with "will" "may", "would", "anticipate", "expect" and other statements about future events, results or outcomes) regarding our belief, intent or expectations with respect to the Company's businesses, market conditions and/or results of operations, and while our management believes reasonable assumptions have been made, the Company's actual results may vary in a material and adverse manner, nothing herein is a guarantee of future performance and you are cautioned not to place undue reliance on such statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. Any investment in the Company is subject to various risks, including but not limited to, our technology and science not meeting current expectations, intellectual property challenges, competition in the market, insufficient customer acquisition, legal and regulatory limitations in certain jurisdictions, privacy issues, among others. Information in this presentation, including financial information, should not be considered as legal, financial or tax advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek your own independent financial, legal and tax advice. ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#31. BUSINESS OVERVIEW COMPANY OVERVIEW CORPORATE OVERVIEW THE PROBLEM OUR SOLUTION DEFENSIBILITY BENEFITS FOR USERS AND COMPANIES GO-TO-MARKET COMPETITIVE ADVANTAGE INVESTMENT LANDSCAPE Brain ResourceⓇ ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#4COMPANY OVERVIEW ABOUT BRAIN RESOURCE Brain Resource® BRAIN RESOURCE IS THE WORLD'S FIRST DIGITAL ASSISTANT FOR BRAIN MONITORING AND TRAINING Brain Resource Ltd. (ASX: BRC) was founded in 2000 by neuroscientist Dr. Evian Gordon, PhD. 660K Users Over 1,000 Clinicians CLINICS Created Neuroscientific Consensus: Our Total Brain has 4 core capacities: Emotion, Feeling, Cognition and Self-Control Each capacity can be measured by 3 core markers (e.g. Cognition: Memory, Focus, Decision) A$50M of R&D delivered scientifically validated digital tools that assess, screen and train the brain at the level of the markers of capacity monitor, Recapitalized in December 2017 with new management team, A$14M in debt conversion (Och-Ziff) and A$10M of working capital raised with public markets institutionals, family offices, and angels Currently scaling platform and diversifying market - powered by the largest standardized neuroscientific database in the world B2B Customers Cerner accenture BOEING Nationwide Channel & Affinity Partners AARP KAISER PERMANENTE® Castlight MERCER Welltok. aetna ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVAD#5CORPORATE OVERVIEW ASX: BRC Market Capitalisation and Enterprise Value Share Price History (A$) 0.040 AUD 0.00 (0.00%) 12 Oct, 3:19 PM GMT+11 Disclaimer Brain ResourceⓇ Ordinary shares on issue m 531.3 1 day 5 days 1 month 6 months YTD 1 year 5 years Max Share price (17 Oct 2018) A$/share 0.04 Market capitalisation A$m $21.3m 0.12 Debt & Convertible Pref's (as at 31 Mar 2018) A$m $0.0m 0.10 Cash (as at 30 Sept 2018) A$m ($4.5m) 0.08 Enterprise Value A$m $16.8m 0.06 WWWW M Top Shareholders (17 Oct 2018) Name HSBC Custody Nominees (Australia) Limited Buttonwood Nominees Pty Limited Stuttgart Pty Limited Top 20 Shareholders 0.04 Dec 2017 Feb 2018 Apr 2018 Jun 2018 Aug 2018 Oct 2018 Board of Directors Shares Held (m) % of Shares Name on Issue Evian Gordon 203.3m 38.3% Louis Gagnon 19.0m 3.6% Ajay Arora 17.6m 3.3% Stephen Koslow 360.5 67.9% Matthew Morgan Position Executive Chairman (CMedO) Managing Director (CEO) Non-Executive Director Non-Executive Director Non-Executive Director ©2018 BRAIN RESOURCE LTD. CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 5#6THE PROBLEM Brain ResourceⓇ WITHOUT OBJECTIVE, ACCESSIBLE AND AFFORDABLE DATA ON OUR OWN BRAIN, WE REALIZE A FRACTION OF OUR POTENTIAL AND MAY UNDULY SUFFER FROM MENTAL HEALTH CONDITIONS 1. Without data on our brain's capacity to process emotions, feelings, cognition, social connections and resilience => we do not optimize our capacity to deliver better work product or relationships - at home or at work 2. Without data on the impact that life events have on our brain capacities => we do not optimize our life choices 3. Without knowing if a mental condition is temporarily impairing our brain capacities => we live through unnecessary misery and cost an incremental $7,000 per year in health care and productivity loss (1),(2) Today: • 20% of the US population is experiencing a mental condition (3) • 50% of the US population will experience a mental condition at least once in their lifetime (4) • 50% of all conditions are undiagnosed/untreated(3) Sources: 1. $1,601 in productivity cost according to Inc Magazine, https://www.inc.com/matthew-jones/how-mental-health-can-save-businesses-225-billion-each-year.htm 2. $5,470 in healthcare cost according to BCBS, The Health of America, "Major Depression: The Impact on Overall Health", May 2018; D. Witters, et. al., "Depression Costs U.S 3. NIMH https://www.nimh.nih.gov/health/statistics/mental-illness.shtml 4. Center for Disease Control, https://www.cdc.gov/mentalhealth/data_publications/index.htm ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#7OUR SOLUTION: DIGITAL ASSISTANT FOR BRAIN MONITORING AND TRAINING Monitor Capacities 20-Minute Clinical Assessment Understanding the Total Brain 12 markers of 4 capacities Screening of 7 Disorders - Brain Performance Context (no stigma) User-Initiated EAP or Professional Referral Attention Brain ResourceⓇ Train Capacities Self-Improvement with Targeted Mind-Body-Brain Training TotalBrain Brain Performance Report JAN 6 2018 Identifying Emotions Your Brain Performance 59th PERCENTILE 12% Higher than 50% of your peers → What Drives Your Performance Emotion Feeling Cognition Self Control Happy Angry 98th Fear Neutral 72nd 45th Disgust Sad 21st Your Brain Performance Has Room to Improve For optimal performance, your brain needs: High emotional capacity. Your Emotion is in the 45th percentile. Clear strength. Your Resilience is your greatest strength. No impairing weakness. Your Mood Control is a weakness but it does not impair your performance. Attention Your performance may be impaired by additional factors LEARN MORE Based on your results, it may be possible that you are experiencing the following: Inattention: Difficulty to complete tasks, distraction, lack of attention to details. forgetfulness ⚫Hyperactivity: Fidgeting, being on-the-go, excessive talking, restlessness Impulsivity: Difficulty inhibiting automatic responses Do these factors impact your daily life in a way that is difficult to cope? If these factors do not impact your daily life, head back to your brain performance report and continue your program. If they do impact your daily life, consider discussing them with a healthcare professional who can determine the best course of action. Boost Your Brain Performance Exercise more, eat better, get more sleep, socialize, and train your brain to master your Anxiety so that your strengths, like your Memory, can function without any hindrance. Recommended Training Embark on a 30-day journey called "Reduce Stress and Stay Calm" that includes: Mindfulness Meditation (Calm and Focus) My Calm Beat (Breathing Exercise) Thought Tamer (Challenge Negative Thoughts) All in just 15 mins a day! BACK NEXT What Drives Your Emotion What Can I Do? Your Next Steps Call Employee Assistance Program at: START JOURNEY ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#8DEFENSIBILITY SOLUTION IS POWERED BY UNIQUE PROPRIETARY ASSETS The ONLY consolidated digital neuroscientific assessment of the Total Brain - Emotion, Feeling, Cognition, Self-Control Clinically validated with 10 publications The world's LARGEST standardized neuroscientific database 1M data sets including 54K EEGs, 542 MRIs, 2K GWAS Database generated over 300 brain research publications 29 Brain Trainings executed 16M times - published impact of trainings on specific performance drivers TLEX Institute Exclusive Partnership - leader in teaching Mind-Body restoration techniques to Fortune 100 companies Brain ResourceⓇ ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#9UNPRECEDENTED BENEFITS FOR END-USERS BRAIN PERFORMANCE ALL USERS 34.1% 34.1% CHALLENGED USERS 2.1% 0.1% 13.6% END-USERS Brain ResourceⓇ PEAK PERFORMERS 2.1% 13.6% 0.1% FOR ALL USERS: ⚫ MONITOR AND TRAIN all capacities for optimal performance at-work and at-home FOR THOSE CHALLENGED BY CONDITIONS: Know impact of condition(s) on brain capacities • Self-monitor impact of meds/therapy on brain capacities • Access data necessary to manage rehabilitation or recovery FOR THOSE PEAK PERFORMERS: Know what exceptional gift(s) drive peak performance Maintain/reinforce advantage ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#10UNPRECEDENTED BENEFITS FOR COMPANIES AND PAYERS BRAIN PERFORMANCE ALL USERS 34.1% 34.1% CHALLENGED USERS 2.1% 0.1% 13.6% PEAK PERFORMERS 2.1% 13.6% 0.1% Brain ResourceⓇ COMPANIES/PAYERS BUSINESS IMPROVEMENT: • Brain training 7% productivity improvement (2017 data, 23 corp. customers) Total solution cost / Productivity benefits of training = avg ROI of 7 • 38% reduction in mental health claims (case study) ⚫ Brain Screening • $8,000 each time undiagnosed case gets to successful treatment ⚫ General Performance • Better brain performance drives better outputs and engagement POPULATION INSIGHTS: • • Custom population benchmark • Brain performance vs. employee data vs demographics Brain performance vs. business performance / talent performance /wellness program effectiveness ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#11GO-TO-MARKET FOCUS AND OPPORTUNITIES H2 CY2018 / CY2019 FOCUS CORPORATE CONSUMER Commercial HR Consumer Affiliates CLINICAL Clinicians Direct B2C Health Systems HRA/EAP CURRENT FOCUS B2B OPPORTUNITIES (Scaling Now) SaaS Platform with Large ACV and Multi-Year Contracts (e.g. Boeing, Accenture) Two Core Products ■ Total Brain Platform ◉ Total Brain Screening B2C OPPORTUNITIES (Testing Now) Consumer Platform with High Potential Average Revenue per User (e.g. Focus@Will) Two Revenue Streams Consumer Subscription ■ ◉ Lead Generation (Advertising) Distribution ■ ◉ 5 Channel Partners (e.g. Mercer) Direct B2B Distribution Consumer Affiliates (e.g. AARP) ◉ Direct B2C Brain ResourceⓇ FUTURE OPPORTUNITIES PAYERS Insurance 11 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#12Brain ResourceⓇ COMPETITIVE ADVANTAGE INTEGRATED APPROACH IN A WORLD OF POINT SOLUTIONS We are the only confidential, self-service, neuroscience-based solution for BRAIN PERFORMANCE MONITORING, SCREENING AND TRAINING MONITORING TRAINING Alternative Solutions Assess and Benchmark All 4 Brain Capacities Through 12 Markers Screen for 7 Mental Health Conditions thru Capacities Mind- Capacity- Body Specific TotalBrain Health Risk Assessments (HRAS) (Wellsuite IV, WebMD, Rallye, Optum, Virgin Pulse, Staywell, Limeade, Provant, Castlight, Aetna, Envolve, Health Status, Medikeeper,) Neuroscientific Assessments (Cambridge Brain Science, Cognifit) Disorder Screening Tools (Public questionnaires, M3, Medibio, Mindstrong) Wellness Solutions (MeQuilibrium, eMindful, Lantern, MyStrength, Whil, MindfulLabs, Headspace, Calm, Happify) Brain Training Apps (BrainHQ, Lumosity) Back-end process. About performance, not disease ✗ General State of Wellness only Physical focus. Few disorders. Stigmatizing X ✗ Cognition only X ✗ Stress-Emotion Only Questionnaires: tedious, stigmatizing X Device tracking: few disorders, invasive, stigmatizing X ✗ X X ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#13INVESTMENT LANDSCAPE THE ONLY PUBLICLY-LISTED PLAY IN MENTAL HEALTH START-UPS SA US$4.5B of capital went to digital health players in Q3 CY2018 alone (1) The Mental Health & Wellness sub-category has received $625M+ in 234 deals since 2013 (2) Brain Resource provides direct public markets exposure to a rapidly-growing segment of tech Brain ResourceⓇ Brain ResourceⓇ COMPANY 1 COMPANY 2 COMPANY 3 COMPANY 4 COMPANY 5 COMPANY 6 COMPANY 7 COMPANY 8 Valuation (USD) / Capital Raised (USD) / $15mm />$40mm / Och Ziff Unknown/ $12mm / $72mm / $26mm / TT LFE Capital Capital Partners $320mm / $74mm / Spectrum Equity $37mm / $22mm / Mayfield Fund $140mm / $79mm / FirstMark Capital $30mm / $25mm / Chrysalis Ventures Unknown/ $7mm Raised / Angels Unknown/ $15mm Raised / Angels Lead Investors Notes A robust platform with a clinically validated assessment, mind-body and brain exercises, deep reporting and analytics, and the ability to impact both emotion and cognition, or the I total brain Mind-body only, no brain exercise; No assessment; 2.5x MBS price Mind-body and brain exercises; weak questionnaire Mind-body only, no brain exercise; No assessment; 50% more than MBS price Mind-body only, no brain exercise; Simple quiz. Brain exercises only, no mind- body; Very focused on memory. Fit test on games, but no clinically validated assessment; 2x MBS price Stress and resilience focused; not brain focused; Limited questionnaire is not a clinical assessment; Dashboard and analytics are basic Mind-body only, no brain exercise; No assessment; 4.5x MBS price Sources: 1. MobiHealthNews 2. CB Insights ©2018 BRAIN RESOURCE LTD. CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 13#142. BUSINESS UPDATE PROGRESS VS. CY2018 OBJECTIVES FINANCIAL UPDATE PRODUCT UPDATE iSPOT UPDATE LOOKING AHEAD CONTACTS Brain ResourceⓇ ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERV4D#15CY2018 OBJECTIVES PROGRESS AS OF 30 SEPTEMBER 2018 OBJECTIVE TIMEFRAME Grow CY2018 total revenue 100% to US$3.2mm (from US$1.6mm in CY17) CY-18 FINANCIAL & USER KPIS PRODUCT 75%+ Recurring SaaS-based revenue (from 60% in CY17) Grow Total User Registrations 100% (from 223k in CY17)* Grown Total Brain Profiles 100% (from 131k in CY17)* Upgrade MBS value proposition, new features & UX Transition to scalable cloud-based software infrastructure Complete ISPOT GWAS, explore Strategic Options Rebrand MBS to TotalBrain CY-18 CY-18 CY-18 CY-18 Q2-18 Q2-18 Q3-18 Enable sale of unmarketable parcel share Q1-18 Appoint 3 New Advisors & 1 New Board Director Q1-18 CORPORATE Complete hiring plan (80%+ completed in Q1 CY2018) Increase media engagement and PR Q1-18 CY-18 Brain ResourceⓇ PROGRESS TO-DATE FINANCIAL KPIs Ongoing. As planned, new product expected to deliver impact in Q4 CY2018, with an additional 2 B2C Affinity contracts launching in Q4 CY2018 PRODUCT Completed. New team, systems, platform, product and brand launched on-time and on- budget CORPORATE Completed Note: User Registrations defined as total individuals who create a registration in Brain Resource system. Brain Profiles defined as number of total assessments captured. ©2018 BRAIN RESOURCE LTD. CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 15#16FINANCIAL UPDATE QUARTERLY CASH RECEIPTS $1,000,000 $800,000 $600,000 $410,000 $400,000 $200,000 Cash Receipts from Customers ($AUD) 21% $497,000 33% $658,715 19% $781,134 18% $919,394 Sep-17 Dec-17 Mar-18 Jun-18 Sep-18 Brain ResourceⓇ 23% AVG. QUARTERLY GROWTH IN CASH RECEIPTS DURING PAST 12 MONTHS TO 5-YEAR HIGH OF A$919K 2.25x INCREASE YEAR-ON-YEAR Focus on cash growth amidst significant operational changes SAAS REVENUE MODEL ENABLING RECURRING REVENUE INCREASE New Total Brain platform and Screening product to drive additional run-rate growth in the coming quarters ©2018 BRAIN RESOURCE LTD. CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 16#17FINANCIAL UPDATE USER KPIs 800,000 600,000 Total Brain Profiles (Cumulative) ■Total User Registrations (Cumulative) 400,000 User Registrations*: 57% CAGR ('14-Sept'18) -- ---- - - -- - --- Brain Profiles*: 59% CAGR ('14-Sept'18) 200,000 Note: 199,767 151,895 114,519 113,028 81,645 0 CY2014 CY2015 296,265 CY2016 367,870 519,387 469,804 CY2017 Brain ResourceⓇ 625,228 Sept 2018 CONTINUED GROWTH IN USER KPIs CY2018 YTD 32% (151k) INCREASE IN USER REGISTRATIONS YEAR-ON-YEAR Achieved without the full benefit of the new Total Brain product (launched in September 2018) or new AARP contract (to be launched in Q4) 45% (145k) INCREASE IN IN BRAIN PROFILES YEAR-ON-YEAR Simplified registration funnel has enabled more rapid user conversion and engagement in CY2018 BIG DATA PLAY Reinforces the value of the neuroscientific database, underpins customer engagement and product development ©2018 BRAIN RESOURCE LTD. CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 17 Table represents cumulative actual figures through the quarter ended 30 September 2018. User Registrations defined as total individuals who create a registration in Brain Resource system. Brain Profiles defined as number of total assessments captured. User Registration figures exclude employer-pre-registered users. Brain Profiles figures include multiple assessments taken by same user.#18Q3 FINANCIAL UPDATE REVENUE GROWTH Q3 YTD CY2016-CY2018 - Calendar Year To Date $A in 000s Total Revenue Y/Y Growth % - MBS/TB Revenue Q3 2016 Q3 2017 Q3 2018 $2,250 $1,525 $2,121 -32%| 39%! $1,248 $1,086 $1,801 Y/Y Growth - % -13% 66%! Recurring Revenue - % 55% 71%i 85%i Contract Won AARP BOEING neuroCare. Nationwide Nationwide Total Contracted Revenue Description Value ($) 2-yr. Direct contract $1,528 Expand to union workers (47k) $230 4-yr. EEG software/data license $150 New Screening product sale $25 $1,933 Brain Resource® CONTINUED GROWTH IN PUBLIC KPIS DURING CY2018 39% Y/Y GROWTH IN TOTAL REVENUE YTD growth reverses negative trajectory from prior period and achieved without the redesigned MBS/TB platform or new screening product sales 66% Y/Y GROWTH IN MBS/TB REVENUE Fueling strategic shift in mix towards recurring SaaS revenue (85% of total) PRE-TOTAL BRAIN LAUNCH MARKET VALIDATION 4 major contracts won ahead of company and product revamp Note: American Association of Retired Persons ("AARP") contract with minimum of A$675k and maximum of A$6M over 2 years. Contractual maximum based on usage tiers and assumes full penetration of AARP's 38mm member base. A$1.5M base case assumes BRC attains 500k users over 2 years. For reference, there were 200k new users from AARP during 2017 via their legacy product and with less marketing support for BRC's solution. 18 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#19B2B PIPELINE GROWTH STRONG SALES LEAD GENERATION CY2018 YTD A$, 000s Brain ResourceⓇ $14,000 Q3 Metric Q3/Q1 Growth # Leads 2,200 4.2x! $12,554 ¡Total Pipeline $12,554 3.7x1 $12,000 Weighted Pipeline $3,766 4.4x Average Contract Value $110 1.9x! $10,000 $8,000 $6,000 ■Total Pipeline $4,000 $2,000 $0 ■Weighted Pipeline $3,437 Mar-18 $851 $7,546 Jun-18 $2,242 Sep-18 $3,766 Note: Figures demonstrate the growing size of the B2B sales opportunity set throughout CY2018. Pipeline represents an annualised amount for the clients that have been qualified as prospective leads by marketing and sales. The 30% weighted conversion rates are an assumption based on where a lead is in the sales cycle. Actual revenue is subject to conversion of pipeline to invoiced sales. SIGNIFICANT GROWTH IN SALES PIPELINE CY2018 YTD 3.7x TOTAL SALES PIPELINE Q3/Q1 AND 4.4x WEIGHTED Driven by a steady q/q increase in marketing leads to 2,200+ currently, and featuring an average % probability weighting of 30% across the pipeline 2x AVERAGE CONTRACT VALUE (ACV) VS. CURRENT TO A$110K+ Driven by the combination of (i.) strategic targeting of larger B2B SaaS contracts, (ii.) increased pricing, and (iii.) screening product offering SCREENING PRODUCT DEMAND DRIVING SHORT-TERM PIPELINE TO HIT CY2018 TARGETS A$200K+ ACV pricing and upfront delivery and recognition under AASB15 19 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#20(1) (2) (3) POTENTIAL OF NEW B2C PARTNERSHIPS TESTING OPPORTUNITIES FOR THE B2C AFFINITY MARKET Initial Target Partner Opportunities Partner Brain Resource® Monthly Visits¹ Focus@Will (executing now) 1M Top Healthcare Portal 1 (pilot planning in process) Top Healthcare Portal 2 (pilot planning in process) Total Addressable Opportunity (Initial 3 Partners) Illustrative Consumer Revenue Opportunity Modeling Subscription Revenue Potential 126M 110M 237M Current targets in stages of partnership and testing. Market opportunity is large. Multiple significant groups to target beyond initial targets. Annual Traffic from Partner 23.6M Lead Generation (Advertising) Revenue Potential Annual Traffic from Partner 23.6M (x) Conversion to Paid Subscription² 0.32% Annual Paid Total Brain Subscribers 74K (x) Conversion to Converted Lead³ Annual Converted Leads 0.04% (x) Subscription Price Annual Subscription Revenue (USD) $65 $4.8M (x) Average Revenue per Lead Annual Advertising Revenue (USD) 8K $329 $3.1M Based on estimated 0.83% monthly traffic penetration across one year; Monetizing consumers with annual subscription and lead generation (advertising) Total Annual Revenue Potential Subscription Revenue Advertising Revenue USD $7.9M $4.8M $3.1M AUD (FX 0.72) $11.0 $6.3 $8.6 Traffic estimates calculated from www.similarweb.com and represent a 6 month traffic average from April 2018 - Sept 2018 Conversion based on estimates of 25% conversion of traffic to registration and 2.5% conversion of registered user to subscription Conversion based on estimates of 25% conversion of traffic to registration and 0.32% conversion of registered user to converted lead OPPORTUNITY TO LEVERAGE AFFINITY GROUPS FOR B2C STRATEGIC PARTNERSHIP WITH FOCUS@WILL Popular streaming service for neuro- optimized music for productivity optimization (1MM active users) PLANNED PILOTS WITH 2 LARGEST U.S. ONLINE HEALTH PLATFORMS Significant opportunity to test the fit and value proposition of Total Brain as a mental health offering for millions of active users FLEXIBILITY TO MONETIZE USERS Able to utilize both a Subscription as well as Lead Generation (Advertising) model LARGE OPPORTUNITY TO SCALE Multiple additional broad and specialized audience platforms to target 20 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#21POTENTIAL REVENUE OPPORTUNITY PENDING B2B PIPELINE CONVERSION AND SUCCESSSFUL B2C TESTING Brain ResourceⓇ B2B PIPELINE OPPORTUNITY (A$,000s) (US$, 000s) B2C PARTNERSHIPS POTENTIAL (A$,000s) (US$, 000s) CY2018 Revenue Forecast $4,444 $3,200 Illustrative B2C Affinity Subscription Revenue $6,667 $4,800 (-) Non-recurring Portion of CY18 Revenue ($356) ($256) Illustrative B2C Affinity Lead Gen Revenue $4,306 $3,100 (+) CY18 YTD B2B Pipeline @ 30% Conversion $3,766 $2,712 (+) Future B2C Affinity Opportunities TBU (+) Future B2B Pipeline Opportunities TBU B2C Partnerships Opportunity (Illustrative) $10,972 $7,900 B2B Recurring Annual Revenue Potential $7,855 $5,656 Note: Figures demonstrate the potential size of the B2B and the illustrative B2C opportunity set and do not represent a revenue forecast. Existing B2B Pipeline represents an annualised amount for the clients that have been qualified as prospective leads by marketing and sales. The 30% weighted conversion rates are an assumption based on where a B2B lead is in the sales cycle. The Illustrative B2C Affinity Subscription Revenue is an example of the size of the opportunity pending successful initial testing. Actual revenue is subject to conversion of the B2B pipeline and B2C opportunities to invoiced sales. 21 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#22PRODUCT UPDATE PLATFORM STRATEGY: BRAIN PERFORMANCE MONITORING, SCREENING AND TRAINING Brain Resource® TODAY EPISODIC BENCHMARK WHY JOIN - ME vs EVERYONE HOW WILL USERS ENGAGE WITH TOTAL BRAIN ---> FUTURE CONTINUOUS SCHEDULED ASSESS Block of Tasks and Questions Short Modules of Tasks and Questions BENCHMARK ME vs. ANYONE REAL TIME Biometrics, External Data Sources, Tasks, Questions TREND DATA Continuous MONITORING RISK SCREENING RECOMMENDATIONS TRAINING SINGLE ASSESSMENT Monthly DISORDERS Seven (more to come) JOURNEYS Structured and Time Bound TREND DATA Monthly SUPPORT Help on Demand PERSONALIZED PATHS Dynamic and Continuous STRUCTURAL TRAINING MBS Brain Training MBS Meditation/Breathing Rebuilt TB Brain Training TLEX Meditation / Breathing MULTIPLE CONDITIONS Challenges AND Peak Performance REAL TIME In the Moment CONTEXTUAL TRAINING Based on schedule / real time data TB and External Calendaring Coaching 22 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#23PRODUCT ROADMAP PRIORITIZATION CORPORATE Commercial HR Education Q4 Roadmap Focus: ◉ Expand Value of Training (impact/ROI) ■ Drive Valuable Engagement (notifications) ■ B2C Affinity (users/brain profiles/$$$) TOTAL BRAIN CONSUMER Consumer Affiliates Direct B2C CURRENT GTM FOCUS Consumer Monetization Brain Resource® CLINICAL Clinicians Health Systems HRA/EAP PAYERS Insurance Clinical Workflows Core Total Brain Platform (Assessment, Training, Screening) TBD PLATFORM NOW NOW 2 6+ Months 2 ~ 6-12 Months + 10s of Millions of Employees $10s of Millions 10s of Millions of Users $10s of Millions 10s of Millions of Employees $10s of Millions 100s of Millions of Users $100s of Millions 23 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#24iSPOT UPDATE Brain Resource® . • BACKGROUND & CURRENT STATUS iSPOT-D (International Study To Predict Optimized Treatment in Depression) was a clinical trial to identify objective predictors of treatment response to 3 of the most-commonly used anti-depressants: Escitalopram (Lexapro), Sertraline (Zoloft), and Venlafaxine- XR (Effexor) 660 genetic variants or "SNPs" from 1,008 patients' bloods were analyzed (cognitive, brain imaging and genetics data) While the current business plan has been focused on the development of MBS (Total Brain), BRC has engaged in a low-energy/high- potential-return project to complete genetics data acquisition • • . The initial scientific analysis with 850k SNPs from a Genome-Wide Association Study was completed according to plan The initial findings suggest positive results for the predictive ability of the iSPOT algorithms for the 3 iSPOT drugs together (i.e. based on the iSPOT test, a patient can find out if any 1 of the 3 drugs will work for them or not) The next step, currently in process, is validating if the same is true for each of the 3 drugs individually (i.e. if the iSPOT test can help a patient find out if which one of the 3 drugs, specifically, will be effective for them) The healthcare investment bank hired to assist with evaluating the strategic alternatives for iSPOT, including licensing, commercialization, and M&A, has continued outreach to potential partners within 4 main verticals: (i.) diagnostics, (ii.) genomics, (iii.) pharmaceuticals, and (iv.) drug development 11 have expressed initial interest to-date and next steps are largely dependent on the findings of the subsequent phase of scientific analysis ©2018 BRAIN RESOURCE LTD. CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 24#25• LOOKING AHEAD CY2018/CY2019 OUTLOOK Brain ResourceⓇ The business is tracking against the corporate objectives, which remain unchanged • 39% year-on-year growth in total revenue and 66% in MBS/Total Brain revenue as of Q3 CY2018YTD • Priority remains to deliver a doubling of user registrations and revenue (to US$3.2m in CY2018). Focused on closing pipeline of immediate Q4 screening opportunities with ACVs of A$200k+ (3.5x+ the current ACV) Execution of Q4 product roadmap is in progress, including engagement tools (e.g. in-app user notifications) and enhanced mind- body training content • The Total Brain launch is the first step towards a vision of a continuous user engagement with the product • · Execution of the Company's B2B go-to-market approach Solidified relationship with channel partners throughout CY2018. New product has been a pre-requisite for validation and increased traction by them (missed Q3 peak season). Just acquired Gold Partner status with Castlight. New partners soon to be announced Company continues to believe that it has a robust solution for EAPS and HRAs. Discussions underway (long cycle) Expansion of the Company's B2C go-to-market approach via affiliates such as AARP and Focus@Will Looking to maximize the size of the recurring revenue opportunity for BRC ©2018 BRAIN RESOURCE LTD. CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 25#26KEY CONTACTS Louis Gagnon CEO, Managing Director Brain Resource Limited [email protected] Matthew Morgan Non-Executive Director Brain Resource Limited [email protected] Nigel Kassulke Director Cannings Communications [email protected] Brain ResourceⓇ FOLLOW US ON: LINKEDIN /the-brain-resource-company in TWITTER @brainresource WEBSITE brainresource.com ©2018 BRAIN RESOURCE LTD. CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 26#273. APPENDIX RESULTS AND CASE STUDIES SCIENCE TEAM Brain ResourceⓇ ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#28Brain ResourceⓇ RESULTS FOR COMPANIES / PAYERS BRAIN PERFORMANCE, RISK MANAGEMENT AND PRODUCTIVITY Reporting Period: Annual 2017 For 23 Corporate Customers • . This report is made available for all customers together with details at the capacity marker level and user demographics when available Screened risk conditions section is illustrative only given the Screening product was launched in September 2018 Overall ALL EMPLOYEES EMPLOYEES WHO TRAIN BRAIN CAPACITY BRAIN CAPACITY n =25,260 (assessed 1 or more) Percentile Rank vs. Last Period 56 +0 n =3,275 (assessed 2X and trained) Overall Percentile Rank 61 vs. Last Period +8 54 -4 Emotion 55 +4 57 -3 Feeling 63 +7 46 -7 Thinking 47 +4 66 +11 Self Regulation 72 +7 Emotion Feeling Thinking Self Regulation Reported Stress and Productivity Highly Stressed < 100% Productive Screened Risk Conditions AT RISK POPULATION % of Initial Assessment # of Emp. vs. Last Period 7.8% 1,470 18.3% 3,403 +2.5% -1.3% Average In-Period Training Time: 3 hrs. Vs Last Period based on 3,275 employees who trained and assessed twice. The 18,759 employees who trained but did not assessed twice most likely experienced similar results to those who did. PRODUCTIVITY n = 1,789 (assessed 2x and high-impact trained) Baseline % of Initial # of Emp. Assessment # Sent to EAP vs. Last Period n = 11,940 (all users who high-impact trained) Post Training Difference Physical Presence (1) Aggregate (4) 12.5% 3,157 1,877 -1.4% Mental Presence(2) 107% 80% Depression 12.1% 3056 1,678 +2.5% Productivity(3) 85.58% 111% 82% 92.73% +4.6% +2% 7.15% Anxiety 8.9% 2240 1,887 -1.3% Addiction 7.3% 1841 998 +1.5% ESTIMATED BENEFIT * $7M PROGRAM COST $0.94M ADHD 8.9% 2239 1,765 +2.1% PTSD 2.1% 543 223 +1.3% *Gross financial result based on self-report of n-1,789 employees who trained and followed up in the period. Productivity difference applies to 11,940 employees who trained on high impact exercises. 11,940 employees x 7.15% difference x 40 hours x 6 weeks (lasting effect of productivity gains) x $35.87 hour Social Anxiety 4.4% 1120 760 -1.9% Sleep Apnea 1.8% 454 220 -1.4% 1) Physical Presence 100% -% of absent hours 2) Mental Presence Employee's self-reported relative performance rating in % 3) Productivity - Physical Presence + Mental Presence ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#29RESULTS FOR COMPANIES / PAYERS: BRAIN PERFORMANCE AND MENTAL HEALTH CLAIMS Brain ResourceⓇ A large US healthcare company tracked and analyzed the change in pharmaceutical claims for employees who used Total Brain to train for better brain performance WHAT WE LEARNED: In the subgroup of people with the poorest sustained attention and anxiety scores, or the bottom 25% of the group: Total pharmaceutical costs during the 2 months before and after Total Brain $400 $350 p = .006 $300 $250 $261 SA There was a $100 reduction in total pharmaceutical cost after using Total Brain for a 2-month period $200 $150 $221 $190 $161 $100 $50 That equals a 38% reduction in cost $- Brain Training $100 decrease (n=69) 2 Months Before Non-training Controls No cost change (n-87) 2 Months After This reduction was not seen for people who registered for Total Brain, but did not go on to participate in any training exercises or fitness games on the site "TotalBrain (formerly MyBrain Solutions) brought on an ability for consumers to engage anytime, anyplace, on their own terms without having to talk to anybody." - VP & Chief Medical Officer * A group analysis in a major U.S. technology company showed that, for its 24% most vulnerable population (those employees with the poorest sustained attention), brain training corresponded with a 38% reduction in pharmaceutical medical claims: $600 in annual savings per employee, if we assume constant training or long lasting effect of 2-month training. ** Our internal data also shows that, for its 25% most vulnerable population of our top-6 clients, brain training corresponds to a cost reduction of 50% for absenteeism (net gain of 7 hours per week at a large US manufacturer) and 28% for presenteeism. ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESED#30THE SCIENCE: TWO UNIQUE NEUROSCIENTIFIC ASSETS Brain ResourceⓇ STANDARDIZED DIGITAL HOLISTIC BRAIN ASSESSMENT (2000-2003) Dr. Evian Gordon, PhD, MD led the world's top neuroscientists over a two-year period in standardizing how to define and measure core brain functions. Standard: 4 Brain Capacities (Thinking + Emotion + Feeling + Self-regulation) can be measured by 12 capacity markers. Example: Thinking is measured by Memory (recall, working), Attention (sustained, controlled) and Executive Function. Asset Created: Digitized the most valid "pen and paper" tests for each brain marker. 5,000 norms were validated over time from more than 386K assessments. A unique asset was created with no market equivalent. There has been 10 scientific publications on the digital assessment alone. STANDARDIZED NEUROSCIENTIFIC DATABASE (2004 - 2017) Digital assessment was part of a suite of standardized data collection tools used by 100s of laboratories and studies. These studies generated new assessments that fed the company's proprietary standardized database. Database Inputs: • • • 200 brain studies at Harvard, NYU, MIT, Stanford, Oxford, Cambridge, etc. Subsequently generated 300 publications (licensing) 20 clinical trials of psychiatric drugs (licensing) 2 clinical trials predicting drug effectiveness for Depression and ADHD - FDA approval possible in 2018 (proprietary) • 600K+ individual brain assessments/brain trainings through employers and clinics (proprietary) Data Types: • 312K Cognitive Performance • 386K Questionnaires .• • • 237K Brain Training Results 2K Genomics 54K EEGs 542 Structural and Functional MRIs 1M standardized data sets: largest in the world and continues to grow in 2018 ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESEBOD#31THE TEAM: EXECUTIVE LEADERSHIP Louis Gagnon, CEO/Managing Director TPG (Ride), Amazon, Yodle Evian Gordon, MD, PhD, CMedO/Chairman Brain Resource (Founder) Matt Mund, COO Monster Worldwide, IBM Marcel Legrand, CRO Vertical Knowledge, Blackfin Capital, Monster Worldwide Matt Resteghini, CMO Randstad Digital Ventures, Monster Worldwide Donna Palmer, PhD, CSO Brain Resource Emil Vasilev, Finance Ride, Corsair Capital, Barclays Capital Meredith Haase, Human Resources Monster Worldwide, Dechert Brain ResourceⓇ ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED#32THE TEAM: SELECT BOARD MEMBERS AND ADVISORS Brain ResourceⓇ Matthew Morgan, Non-Executive Director Millers Point, Sensera, Think Mobility, Leaf Resources, Diversa, QIC Ajay Arora, Non-Executive Director Netflix, Imgur, Amazon Steve Koslow, PhD, Non-Executive Director Inaugural Director of the Human Brain Project at National Institute of Mental Health; 90 publications and 20 book chapters Johann Berlin, Content Partner TLEX Institute, Business Insider Barbara Van Dahlen, PhD, Advisor - Mental Health Founder/President of Give an Hour TIME's Magazine 100 Most Influential People in the World Patrick Manzo, Advisor - Privacy/Security Monster Worldwide Christopher Dolan, Advisor - Technology Sonos, ANSWR, Monster Worldwide John Rush, MD, Advisor - iSPOT (Depression) Internationally-acclaimed depression psychiatrist One of the "World's Most Influential Scientific Minds" according to Thomson Reuters Columbia, MD; Princeton, BS Glen Elliott, PhD, MD, Advisor - iSPOT (ADHD) Child and adolescent psychiatrist at Stanford Principal Investigator in the largest study in improving the diagnosis and treatment of ADHD David Whitehouse, Advisor - Health Systems 25 years of C-level experience in health care Former Chief Marketing and Medical Officer for Optum Health (part of United Insurance) ©2018 BRAIN RESOURCE LTD. - CONFIDENTIAL MATERIAL ALL RIGHTS RESEBZD

Download to PowerPoint

Download presentation as an editable powerpoint.

Related

Q4 & FY22 - Investor Presentation image

Q4 & FY22 - Investor Presentation

Financial Services

FY23 Results - Investor Presentation image

FY23 Results - Investor Presentation

Financial Services

Ferocious - Plant Growth Optimizer image

Ferocious - Plant Growth Optimizer

Agriculture

Market Outlook and Operational Insights image

Market Outlook and Operational Insights

Metals and Mining

2023 Investor Presentation image

2023 Investor Presentation

Financial

Leveraging EdTech Across 3 Verticals image

Leveraging EdTech Across 3 Verticals

Technology

Axis 2.0 Digital Banking image

Axis 2.0 Digital Banking

Sustainability & Digital Solutions

Capital One’s acquisition of Discover image

Capital One’s acquisition of Discover

Mergers and Acquisitions